Ofatumumab Multiple Sclerosis Real-World Experience Study

ClinicalTrials.gov published registration details for NCT07504783, an observational study evaluating ofatumumab effectiveness and safety in multiple sclerosis patients under routine clinical care conditions. The study captures real-world evidence (RWE) on treatment outcomes, patient-reported results, and clinical observations. Ofatumumab is an FDA-approved anti-CD20 monoclonal antibody for relapsing forms of MS.

Pharmaceutical manufacturers and healthcare providers conducting or sponsoring applicable clinical trials must ensure proper ClinicalTrials.gov registration under federal requirements. Patients with multiple sclerosis may wish to discuss with their neurologists whether participation in this or similar real-world evidence studies is appropriate for their treatment journey. ClinicalTrials.gov registrations must be updated with results within 12 months of the primary completion date for applicable trials.